{'52WeekChange': -0.09469348,
 'SandP52WeekChange': 0.0644362,
 'address1': 'Connaught House',
 'address2': '1 Burlington Road',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 19.76,
 'askSize': 2900,
 'averageDailyVolume10Day': 1693037,
 'averageVolume': 1578628,
 'averageVolume10days': 1693037,
 'beta': 1.492997,
 'beta3Year': None,
 'bid': 16.5,
 'bidSize': 800,
 'bookValue': 6.699,
 'category': None,
 'circulatingSupply': None,
 'city': 'Dublin',
 'companyOfficers': [],
 'country': 'Ireland',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 19.88,
 'dayLow': 19.13,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -72.256,
 'enterpriseToRevenue': 2.546,
 'enterpriseValue': 3039646208,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 18.735144,
 'fiftyTwoWeekHigh': 23.5,
 'fiftyTwoWeekLow': 11.98,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 157029400,
 'forwardEps': 0.41,
 'forwardPE': 48.268295,
 'fromCurrency': None,
 'fullTimeEmployees': 2235,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.00915,
 'heldPercentInstitutions': 0.96659,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 958348800,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/alkermes.com',
 'longBusinessSummary': 'Alkermes plc, a biopharmaceutical company, '
                        'researches, develops, and commercializes '
                        'pharmaceutical products to address unmet medical '
                        'needs of patients in various therapeutic areas in the '
                        'United States, Ireland, and internationally. Its '
                        'marketed products include ARISTADA (aripiprazole '
                        'lauroxil), an extended-release intramuscular '
                        'injectable suspension for the treatment of '
                        'schizophrenia; VIVITROL (naltrexone for '
                        'extended-release injectable suspension) for the '
                        'treatment of alcohol and opioid dependence; RISPERDAL '
                        'CONSTA for the treatment of schizophrenia and bipolar '
                        'I disorder; INVEGA SUSTENNA for the treatment of '
                        'schizophrenia and schizoaffective disorder; XEPLION, '
                        'INVEGA TRINZA, and TREVICTA for treating '
                        'schizophrenia; and VUMERITY (diroximel fumarate) for '
                        'the treatment of relapsing forms of multiple '
                        'sclerosis in adults, including clinically isolated '
                        'syndrome, relapsing-remitting and active secondary '
                        'progressive diseases. The company is also ALKS 3831 '
                        'to treat schizophrenia; and ALKS 4230, an engineered '
                        'fusion protein to expand tumor-killing immune cells '
                        'and to avoid activation of immunosuppressive cells. '
                        'It has collaboration agreements with Janssen '
                        'Pharmaceutica N.V., Janssen Pharmaceutica Inc, and '
                        'Janssen Pharmaceutica International; license '
                        'agreement with Acorda Therapeutics, Inc.; and license '
                        'and collaboration agreement with Biogen Swiss '
                        'Manufacturing GmbH. Alkermes plc was founded in 1987 '
                        'and is headquartered in Dublin, Ireland.',
 'longName': 'Alkermes plc',
 'market': 'us_market',
 'marketCap': 3141445120,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_24572',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -138876000,
 'nextFiscalYearEnd': 1640908800,
 'open': 19.59,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -81.87,
 'phone': '353 1 772 8000',
 'previousClose': 19.65,
 'priceHint': 2,
 'priceToBook': 2.9541724,
 'priceToSalesTrailing12Months': 2.6308827,
 'profitMargins': -0.1163,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 19.88,
 'regularMarketDayLow': 19.13,
 'regularMarketOpen': 19.59,
 'regularMarketPreviousClose': 19.65,
 'regularMarketPrice': 19.59,
 'regularMarketVolume': 1843212,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 158739008,
 'sharesPercentSharesOut': 0.075100005,
 'sharesShort': 11917038,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 10911073,
 'shortName': 'Alkermes plc',
 'shortPercentOfFloat': 0.107,
 'shortRatio': 8.02,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'ALKS',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.882,
 'twoHundredDayAverage': 17.302446,
 'volume': 1843212,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.alkermes.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '4'}